Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.
Scientists at St. Jude Children's Research Hospital have shown how a protein responsible for adapting to low oxygen conditions (hypoxia), causes increased expression of fetal hemoglobin (HbF) in adults.
Adding erythropoietin to cooling therapy for term newborns with birth asphyxia has no benefit over cooling therapy alone, a study published today in the New England Journal of Medicine.
Many proteins in nature exist as glycoproteins, which consist of protein (polypeptide chain) and glycan (sugar chain).
A research team at Kyoto University has revealed characteristic behaviors of erythropoietin (Epo)-producing cells.
Anemia is a common and sometimes debilitating problem among patients with chronic kidney disease (CKD). Anemia can occur when the kidneys become damaged, limiting the production of erythropoietin (EPO) -; a hormone that signals to the body to make red blood cells.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.
Pooled results from recent clinical trials indicate that an oral drug called roxadustat is an effective treatment for anemia in patients with chronic kidney disease.
Every year there are nearly ten million new cases of dementia globally, of which Alzheimer's Disease (AD) is the most common form, accounting for around 60-70% of cases.
SGLT2 inhibitors (gliflozins) were developed as oral antidiabetics. They enhance urinary glucose excretion by inhibiting SGLT-2 (sodium-dependent glucose co-transporter-2) in the renal tubuli.
Erythropoietin (EPO) is a medication used to stimulate the production of new red blood cells, which is impaired in individuals with kidney failure. Unfortunately, however, the treatment may increase the risk of hip fractures.
The current COVID-19 pandemic has caused over 1 million deaths which can be attributed to its severe progressive pulmonary compromise.
Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies.
Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.
Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against Covid-19.
Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals.
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma.
One promising way to treat diabetes is with transplanted islet cells that produce insulin when blood sugar levels get too low.
A study published in the Jan 16 edition of the New England Journal of Medicine suggests that erythropoietin treatment may not provide neuroprotection for extremely premature babies.
The hormone erythropoietin (Epo) is a well-known doping substance that has a long history of abuse in endurance sports, such as cycling. In addition to promoting red blood cell production (erythropoiesis), which improves the oxygen supply in the organism, Epo also protects nerve cells from cell death.
The kidney is an organ not only for excreting body waste by urine but also for maintaining body homeostasis in close cooperation with other organs.